ASCO 2014: Lilly's Cyramza REVELs in slight lung cancer OS advance
This article was originally published in Scrip
Eli Lilly's novel anti-angiogenesis monoclonal antibody product ramucirumab (Cyramza) extended life in lung cancer patients by an average of six weeks in the Phase III REVEL study, the full data presented at ASCO this weekend show. While not huge, the difference is enough to lead analysts to believe that the drug will be able to expand its indication into this additional market –Lilly is expected to file later this year.
You may also be interested in...
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.
The German biotech firm has denied receiving any offer from the Trump administration in a wide-ranging conference call that also addressed recent changes at the top, its clinical timeline for a coronavirus vaccine and new funds from the European Commission to boost production.